Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582618 · ClinicalTrials.gov registry record · Phase 2
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by TaiRx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03582618 is a Phase 2 study that was terminated before completion, run by TaiRx. The registered enrollment target is 12 participants.
The verdict
NCT03582618, a Phase 2 study, was terminated before completion, sponsored by TaiRx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.
Interventions
- DRUG Sorafenib
- DRUG CVM-1118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03582618
The ClinicalTrials.gov registry entry for NCT03582618 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TaiRx, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT03582618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03582618 about?
NCT03582618 is a clinical study titled "CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma". CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the...
What is the current status of trial NCT03582618?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-07-12. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT03582618?
The interventions under investigation include: Sorafenib (DRUG), CVM-1118 (DRUG).
Who is sponsoring clinical trial NCT03582618?
This trial is sponsored by TaiRx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.